Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 4, pp 641–656 | Cite as

Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions

  • Edeltraut KrögerEmail author
  • Ovidiu Tatar
  • Isabelle Vedel
  • Anik M. C. Giguère
  • Philippe Voyer
  • Laurence Guillaumie
  • Jean-Pierre Grégoire
  • Line Guénette
Review Article

Abstract

Background Medication non-adherence may lead to poor therapeutic outcomes. Cognitive functions deteriorate with age, contributing to decreased adherence. Interventions have been tested to improve adherence in seniors with cognitive impairment or Alzheimer disease (AD), but high-quality systematic reviews are lacking. It remains unclear which interventions are promising. Objectives We conducted a systematic review to identify, describe, and evaluate interventions aimed at improving medication adherence among seniors with any type of cognitive impairment. Methods Following NICE guidance, databases and websites were searched using combinations of controlled and free vocabulary. All adherence-enhancing interventions and study designs were considered. Studies had to include community dwelling seniors, aged 65 years or older, with cognitive impairment, receiving at least one medication for a chronic condition, and an adherence measure. Study characteristics and methodological quality were assessed. Results We identified 13 interventions, including six RCTs. Two studies were of poor, nine of low/medium and two of high quality. Seven studies had sample sizes below 50 and six interventions focused on adherence to AD medication. Six interventions tested a behavioral, four a medication oriented, two an educational and one a multi-faceted approach. Studies rarely assessed therapeutic outcomes. All but one intervention showed improved adherence. Conclusion Three medium quality studies showed better adherence with patches than with pills for AD treatment. Promising interventions used educational or reminding strategies, including one high quality RCT. Nine studies were of low/moderate quality. High quality RCTs using a theoretical framework for intervention selection are needed to identify strategies for improved adherence in these seniors.

Keywords

Adherence Alzheimer disease Cholinesterase inhibitors Cognitive impairment Community-dwelling seniors Systematic review 

Notes

Acknowledgements

The authors wish to thank the research professionals who worked on this review, Ms Martine Marcotte and Ms Laura Finken, as well as a resident in geriatric medicine who participated in the article selection, Dr Pierre Molin. They also wish to thank Dr. André Tourigny from the CEVQ who was instrumental in initiating this research, and Ms Zorica Djordjevic, librarian at the Hôpital St-Sacrement du CHU de Québec, who contributed to the database search strategy.

Funding

Chair on adherence to treatments, Université Laval (EKröger) and from the Centre d’excellence sur le vieillissement de Québec (CEVQ) and the Réseau québécois de recherche sur le vieillissement du Fonds de recherche du Québec—santé (E Kröger)

Conflicts of interest

None of the authors have any conflict of interest to declare.

References

  1. 1.
    Ramage-Morin PL. Medication use among senior Canadians. Health Rep. 2009;20:37–44.PubMedGoogle Scholar
  2. 2.
    Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2012. Ottawa, ON. May 2014.Google Scholar
  3. 3.
    National Center for Health Statistics. Health, United States, 2014: In Brief. Hyattsville, MD2014. DHHS Publication No. 2015–1210.Google Scholar
  4. 4.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.CrossRefPubMedGoogle Scholar
  5. 5.
    Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppart T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kröger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27:663–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.Google Scholar
  8. 8.
    Perreault S, Ellia L, Dragomir A, Cote R, Blais L, Berard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122:647–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Perreault S, Yu AY, Cote R, Dragomir A, White-Guay B, Dumas S. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Arlt S, Lindner R, Rosler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275:214–28.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tuokko H, Morris C, Ebert P. Mild cognitive impairment and everyday functioning in older adults. Neurocase. 2005;11:40–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Panza F, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry. 2005;13:633–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement J Alzheimers Assoc. 2012;8:14–21.CrossRefGoogle Scholar
  19. 19.
    Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312:2551–61.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bickel H, Mosch E, Seigerschmidt E, Siemen M, Forstl H. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dement Geriatr Cogn Disord. 2006;21:242–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Alzheimer’s Disease International, Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London, UK, August 2015.Google Scholar
  23. 23.
    Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol. 2001;57:589–94.CrossRefPubMedGoogle Scholar
  24. 24.
    Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.CrossRefPubMedGoogle Scholar
  25. 25.
    Luzny J, Ivanova K, Jurickova L. Non-adherence in seniors with dementia—a serious problem of routine clinical practice. Acta Med (Hradec Kralove). 2014;57:73–7.CrossRefGoogle Scholar
  26. 26.
    Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.Google Scholar
  27. 27.
    Van Eijken M, Tsang S, Wensing M, De Smet PAGM, Grol RPTM. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging. 2003;20:229–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30:33–43.CrossRefPubMedGoogle Scholar
  29. 29.
    George J, Elliott RA, Stewart DC. A systematic review of interventions to improve medication taking in elderly patients prescribed multiple medications. Drugs Aging. 2008;25:307–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Banning M. A review of interventions used to improve adherence to medication in older people. Int J Nurs Stud. 2009;46:1505–15.CrossRefPubMedGoogle Scholar
  31. 31.
    Conn VS, Hafdahl AR, Cooper PS, Ruppar TM, Mehr DR, Russell CL. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials. Gerontologist. 2009;49:447–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10:165–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59:624–31.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from www.handbook.cochrane.org.
  35. 35.
    National Institute for Health and Care Excellence. Methods for the development of NICE public health guidance. 3rd ed. London: National Institute for Health and Care Excellence; 2012. https://www.nice.org.uk/process/pmg4/chapter/appendix-f-quality-appraisal-checklist-quantitative-intervention-studies.
  36. 36.
    Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.Google Scholar
  37. 37.
    Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20:267–78.CrossRefGoogle Scholar
  38. 38.
    van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hawkins LA, Firek CJ. Testing a novel pictorial medication sheet to improve adherence in veterans with heart failure and cognitive impairment. Heart Lung J Crit Care. 2014;43:486–93.CrossRefGoogle Scholar
  40. 40.
    Insel KC, Cole L. Individualizing memory strategies to improve medication adherence. Appl Nurs Res. 2005;18:199–204.CrossRefPubMedGoogle Scholar
  41. 41.
    Kripalani S, Schmotzer B, Jacobson TA. Improving medication adherence through graphically enhanced interventions in coronary heart disease (IMAGE-CHD): a randomized controlled trial. J Gen Intern Med. 2012;27:1609–17.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563–71.CrossRefPubMedGoogle Scholar
  43. 43.
    Leirer VO, Morrow DG, Tanke ED, Pariante GM. Elders’ nonadherence: its assessment and medication reminding by voice mail. Gerontologist. 1991;31:514–20.CrossRefPubMedGoogle Scholar
  44. 44.
    Ownby RL, Hertzog C, Czaja SJ. Tailored information and automated reminding to improve medication adherence in Spanish- and English-speaking elders treated for memory impairment. Clin Gerontol. 2012;35:221–38.CrossRefGoogle Scholar
  45. 45.
    Smith GE, Lunde AM, Hathaway JC, Vickers KS. Telehealth home monitoring of solitary persons with mild dementia. Am J Alzheimer’s Dis Other Dement. 2007;22:20–6.CrossRefGoogle Scholar
  46. 46.
    Tian H, Abouzaid S, Chen W, Kahler KH, Kim E. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord. 2013;27:182–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract. 2014;68:465–70.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Oswald WD, Gunzelmann T, Wannenmacher W. Die Compliance von Patienten höheren Lebensalters mit Hirnleistungsstörungen bei Encephabol forte und Encephabol 600 [Compliance of patients with dementia syndrome treated with Encephabol forte and Encephabol 600]. Z Gerontopsychologie Psychiatr. 1993;6:17–25.Google Scholar
  49. 49.
    Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease. Expert Rev Neurother. 2012;12:31–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Kamimura T, Ishiwata R, Inoue T. Medication reminder device for the elderly patients with mild cognitive impairment. Am J Alzheimer’s Dis Other Dement. 2012;27:238–42.CrossRefGoogle Scholar
  51. 51.
    Watanabe N, Yamamura K, Suzuki Y, Umegaki H, Shigeno K, Matsushita R, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605–11.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Folstein MF, Folstein SE, McHugh PR. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMedGoogle Scholar
  54. 54.
    Tariq SH, Tumosa N, Chibnall JT, Perry MH 3rd, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. Am J Geriatr Psychiatry. 2006;14:900–10.CrossRefPubMedGoogle Scholar
  55. 55.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.CrossRefPubMedGoogle Scholar
  56. 56.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006; CD005593.Google Scholar
  57. 57.
    Kröger E, Mouls M, Wilchesky M, Berkers M, Carmichael PH, van Marum R, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. Ann Pharmacother. 2015;31:1197–206.CrossRefGoogle Scholar
  58. 58.
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRefPubMedGoogle Scholar
  59. 59.
    Khan KS, Dinnes J, Kleijnen J. Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol. 2001;95:6–11.CrossRefPubMedGoogle Scholar
  60. 60.
    Popay J, Roberts H, Sowden A, Petticrew M, Arai Y, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. 1st ed. Lancaster: Institute for Health Research, Bowland Tower East Wing, Lancaster University; 2006.Google Scholar
  61. 61.
    Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16:CD000011.Google Scholar
  62. 62.
    Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36:26–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014;201:390–2.CrossRefPubMedGoogle Scholar
  64. 64.
    Reeve E, Turner JP. Patients’ perspectives on the brave new word ‘deprescribing’. Int J Pharm Pract. 2015;23:90–1.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Edeltraut Kröger
    • 1
    • 2
    • 6
    Email author
  • Ovidiu Tatar
    • 3
  • Isabelle Vedel
    • 3
  • Anik M. C. Giguère
    • 1
    • 4
    • 6
  • Philippe Voyer
    • 1
    • 5
    • 6
  • Laurence Guillaumie
    • 5
    • 6
    • 7
  • Jean-Pierre Grégoire
    • 2
    • 6
    • 7
  • Line Guénette
    • 2
    • 6
    • 7
  1. 1.Centre d’excellence sur le vieillissement de Québec, Axe Santé des populations et pratiques optimales en santéCentre intégré universitaire des soins et services de santé de la Capitale nationaleQuebec CityCanada
  2. 2.Faculty of PharmacyUniversité LavalQuebec CityCanada
  3. 3.Department of Family MedicineMcGill UniversityMontrealCanada
  4. 4.Département de médecine de famille et de médecine d’urgenceUniversité LavalQuebec CityCanada
  5. 5.Faculté des sciences infirmièresUniversité LavalQuebec CityCanada
  6. 6.Population Health and Optimal Health Practices Research UnitCHU de Québec – Université Laval Research CenterQuebec CityCanada
  7. 7.Chair on Adherence to TreatmentUniversité LavalQuebec CityCanada

Personalised recommendations